Log in

CNSX:BUXBioMark Diagnostics Stock Price, Forecast & News

$0.12
0.00 (0.00 %)
(As of 05/22/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.12
Now: $0.12
$0.12
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Biomark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions that allows for cancer detection, monitoring, and assessing treatment. The company was incorporated in 2014 and is headquartered in Richmond, Canada. Biomark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars


Industry, Sector and Symbol

Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone604-370-0779

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive BUX News and Ratings via Email

Sign-up to receive the latest news and ratings for BUX and its competitors with MarketBeat's FREE daily newsletter.

BioMark Diagnostics (CNSX:BUX) Frequently Asked Questions

Has BioMark Diagnostics been receiving favorable news coverage?

Press coverage about BUX stock has trended somewhat negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BioMark Diagnostics earned a news impact score of -1.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutBioMark Diagnostics.

Who are some of BioMark Diagnostics' key competitors?

Who are BioMark Diagnostics' key executives?

BioMark Diagnostics' management team includes the following people:
  • Mr. Rashid Ahmed Bux, Founder, CEO, Pres & Director
  • Mr. Brian Cheng, CTO & Director
  • Gina Huang, CFO & Project Director
  • Dr. Thomas Malcolm Ph.D., Chief Scientific Officer
  • Neal Kaplan, Chief Financial Officer of US

What is BioMark Diagnostics' stock symbol?

BioMark Diagnostics trades on the CNSX under the ticker symbol "BUX."

How do I buy shares of BioMark Diagnostics?

Shares of BUX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioMark Diagnostics' stock price today?

One share of BUX stock can currently be purchased for approximately $0.12.

What is BioMark Diagnostics' official website?

The official website for BioMark Diagnostics is www.biomarkdiagnostics.com.

How can I contact BioMark Diagnostics?

The company can be reached via phone at 604-370-0779.

This page was last updated on 5/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.